Phase 3Active, not recruiting
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS)
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)
- Sponsor
- NewAmsterdam Pharma (Industry)
- Enrollment
- 300 planned
- Conditions
- Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)
- Interventions
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily; Obicetrapib 10 mg; Placebo
- Ages
- adults, older adults
- Registry
- NCT07219602
Full record on ClinicalTrials.gov
From the registry
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.
Primary outcomes
- The percent change from Baseline to Day 84 in LDL-C compared with placebo for the following treatment groups: - obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group; and - obicetrapib 10 mg monotherapy treatment group
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered